Amicus Therapeutics to Be Acquired by BioMarin

Amicus ( (FOLD) ) has shared an update.

On December 19, 2025, Amicus Therapeutics agreed to be acquired by BioMarin Pharmaceutical in an all-cash transaction valuing Amicus at approximately $4.8 billion, or $14.50 per share, a premium of up to 58% over recent trading averages; following closing—expected in the second quarter of 2026 pending antitrust clearances and shareholder approval—Amicus will become a wholly owned BioMarin subsidiary, with Amicus shareholders cashed out and equity awards converted to cash. The deal will add Galafold and Pombiliti + Opfolda to BioMarin’s rare-disease portfolio, immediately boosting revenue growth, diversifying its enzyme therapy franchise and, according to the companies, becoming accretive to non-GAAP EPS within 12 months of closing and substantially accretive from 2027, financed via a mix of cash and about $3.7 billion of new debt; a $175 million termination fee and a suite of no-shop and fiduciary-out provisions govern competing bids, while a separate settlement of U.S. patent litigation over Galafold grants generic challengers licenses starting in 2037, effectively extending U.S. market exclusivity and bolstering the long-term value of the asset within BioMarin’s portfolio.

The most recent analyst rating on (FOLD) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on Amicus stock, see the FOLD Stock Forecast page.

Spark’s Take on FOLD Stock

According to Spark, TipRanks’ AI Analyst, FOLD is a Neutral.

Amicus Therapeutics shows strong technical momentum and positive earnings call sentiment, indicating potential for growth. However, financial performance challenges and valuation concerns weigh on the overall score.

To see Spark’s full report on FOLD stock, click here.

More about Amicus

Amicus Therapeutics is a biotechnology company focused on developing and commercializing therapies for rare diseases, with a particular emphasis on lysosomal storage disorders. Its key marketed products include Galafold (migalastat), the first oral treatment for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) plus Opfolda (miglustat), a two-component therapy for Pompe disease, which together generated $599 million in net product revenue over the past four quarters and are sold globally. Amicus also holds U.S. rights to DMX-200, a potential first-in-class small molecule in Phase 3 development for focal segmental glomerulosclerosis, a rare kidney disease.

Average Trading Volume: 5,282,105

Technical Sentiment Signal: Buy

Current Market Cap: $3.39B

See more insights into FOLD stock on TipRanks’ Stock Analysis page.